Author: Scott Deeter
VERO Expansion in the iCellis® Bioreactor with Chemically Defined and Blood Free Virus Production Media
Introduction Manufacturing vaccines for both preventative and therapeutic applications requires the production of large amounts of virus from host cell substrates. Increased demand for these viral products has induced a major shift in the model of viral vaccine manufacturing from more primitive platforms, such as embryonated chicken eggs (ECE), to more robust large-scale methods that …
High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation
Introduction Cell therapy offers a novel approach to medicine, leveraging the body’s own cellular machinery to treat a variety of indications in regenerative medicine, immune disease, and cancer.1 Since the mid 1990s, scientists have been exploring ways to create robust and reliable manufacturing systems leveraging high-quality, well-defined, GMP (Good Manufacturing Practice)-grade raw materials.2,3 Traditionally sourced …